A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2016
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms FUNCTION LTE
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jul 2014 Planned End Date changed from 1 Dec 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov record.